Stock Mover of The Day: Corbus Pharmaceuticals Holdings Inc’s Trend Down, Especially After Today’s Weak Session

Stock Mover of The Day: Corbus Pharmaceuticals Holdings Inc's Trend Down, Especially After Today's Weak Session

The stock of Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) is a huge mover today! About 722,467 shares traded hands. Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) has risen 252.42% since April 27, 2016 and is uptrending. It has outperformed by 247.20% the S&P500.
The move comes after 5 months negative chart setup for the $325.34M company. It was reported on Nov, 30 by We have $7.02 PT which if reached, will make NASDAQ:CRBP worth $22.77 million less.

Analysts await Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) to report earnings on April, 4. They expect $-0.11 EPS, down 83.33% or $0.05 from last year’s $-0.06 per share. After $-0.12 actual EPS reported by Corbus Pharmaceuticals Holdings Inc for the previous quarter, Wall Street now forecasts -8.33% EPS growth.

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Ratings Coverage

Out of 4 analysts covering Corbus Pharma (NASDAQ:CRBP), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Corbus Pharma has been the topic of 4 analyst reports since September 8, 2015 according to StockzIntelligence Inc. On Wednesday, October 5 the stock rating was initiated by Cantor Fitzgerald with “Buy”. JMP Securities initiated it with “Mkt Outperform” rating and $6.0 target price in Tuesday, September 8 report. As per Monday, March 7, the company rating was initiated by Aegis Capital. As per Friday, November 11, the company rating was maintained by Noble Financial.

According to Zacks Investment Research, “Corbus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics to treat life threatening (orphan) inflammatory-fibrotic diseases. The Company’s lead product is Resunab (TM), an oral anti-inflammatory drug that has completed Phase I clinical trials for the treatment of cystic fibrosis and scleroderma. Corbus Pharmaceuticals Holdings, Inc. is based in Norwood, Massachusetts.”

More recent Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) news were published by: which released: “Why Corbus Pharmaceuticals Holdings Inc. Skyrocketed Higher Today” on November 14, 2016. Also published the news titled: “Why Corbus Pharmaceuticals Holdings Inc Jumped Higher Today” on October 19, 2016.‘s news article titled: “Why Corbus Pharmaceuticals Holdings Inc Shares Skyrocketed Today” with publication date: October 05, 2016 was also an interesting one.

CRBP Company Profile

Corbus Pharmaceuticals Holdings, Inc., incorporated on December 18, 2013, is a clinical-stage pharmaceutical company. The Firm is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases. The Company’s product, Resunab, is a synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Resunab is being evaluated in approximately three separate Phase II studies for the treatment of cystic fibrosis (CF), systemic sclerosis and skin-predominant dermatomyositis. The United States Food and Drug Administration (the FDA) has granted Resunab Orphan Drug Designation, as well as Fast Track Status, for both cystic fibrosis and systemic sclerosis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment